ANP Share Price

Open 0.03 Change Price %
High 0.03 1 Day 0.00 0.00
Low 0.03 1 Week 0.00 0.00
Close 0.03 1 Month 0.00 0.00
Volume 109501 1 Year -0.02 -40.00
52 Week High 0.06
52 Week Low 0.03
ANP Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.03
Support 1 0.03
Support 2 0.03
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TLS 4.48 -0.22%
TLS 4.48 -0.22%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
RXL 0.02 100.00%
RXL 0.02 100.00%
RXL 0.02 100.00%
BNV 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
BYR 0.05 25.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
PTR 0.01 -50.00%
PTR 0.01 -50.00%
PTR 0.01 -50.00%
POH 0.01 -50.00%
RMG 0.01 -50.00%
More..

Antisense Therapeutics Ltd (ASX: ANP)

ANP Technical Analysis 5
As on 23rd May 2017 ANP Share Price closed @ 0.03 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.04 & Strong Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
ANP Target for May
1st Target up-side 0.04
2nd Target up-side 0.04
3rd Target up-side 0.04
1st Target down-side 0.02
2nd Target down-side 0.02
3rd Target down-side 0.02
ANP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.antisense.com.au
ANP Address
ANP
6 - 8 Wallace Avenue
Toorak, VIC 3142
Australia
Phone: 61 3 9827 8999
Fax: 61 3 9827 1166
ANP Latest News
Watching the Tape Move for Antisense Therapeutics Ltd (ANP.AX)   The Times   - 19th May 17
Antisense Therapeutics Ltd (ATHJF) Needle Moving on Volume   Concord Register   - 18th May 17
Acromegaly Pipeline and Therapeutic Assessment, Drug Development by Companies ...   Digital Journal   - 18th May 17
Unusual Activity Spotted in Antisense Therapeutics Ltd (ANP.AX)   Concord Register   - 04th Apr 17
Global Acromegaly Pipeline Review, H2 2016: Therapeutics Analysis of 16 ...   Business Wire (press release)   - 21st Oct 16
Antisense Therapeutics Limited in ASX trading halt   Proactive Investors Australia   - 07th Mar 16
Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement ...   Business Wire (press release)   - 15th May 15
ATL1102 for MS - Phase II trial results published in the leading Medical ...   PR Newswire (press release)   - 22nd Sep 14
Acromegaly and antisense therapy: an interview with Mark Diamond, CEO ...   News-Medical.net   - 26th Aug 14
ATL1103 Acromegaly Phase II Trial Recruitment Completed   PR Newswire (press release)   - 21st Mar 14
Interactive Technical Analysis Chart Antisense Therapeutics Ltd ( ANP ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Antisense Therapeutics Ltd
ANP Business Profile
Antisense Therapeutics Limited develops and commercializes novel antisense therapeutics in the United States, Canada, Japan, Australia, and Europe. The company’s product pipeline comprises ATL1103, a Phase II clinical trial drug to block growth hormone receptor expression and reduce the levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action, including acromegaly, diabetic retinopathy, diabetic nephropathy, and various cancers. Its product pipeline also includes ATL1102 as a Phase II antisense inhibitor of CD49d to treat multiple sclerosis; a research stage antisense compound targeting the VLA-4 molecule for the treatment of asthma; and a preclinical stage product for stem cell mobilization in stem cell transplantation, as well as ATL1101, a preclinical stage antisense inhibitor of insulin like growth factor 1 receptor for the treatment of prostate cancer. The company has strategic alliance and license agreement with Tianjin International Joint Academy of Biotechnology and Medicine for the development and commercialization of ATL1102, as well as strategic partnership with Isis Pharmaceuticals Inc. to access antisense technology. Antisense Therapeutics Limited is based in Toorak, Australia.